Publication | Closed Access

Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study

UrologyGenitourinary CancerMedicineImmune Checkpoint InhibitorFirst-line TreatmentAnti-cancer AgentKeynote-426 StudyCancer TreatmentOncologyRadiation OncologyMolecular OncologyPhase 3